CRMD · CorMedix Inc.
AI read · Good for CRMD
The AI's read
CorMedix reported a clean quarter: adjusted EPS 29c vs 25c est, revenue doubled to $101.9M with $66.1M from DefenCath and a big EBITDA jump. Management reaffirmed 2026 sales guidance and raised adjusted EBITDA guidance while announcing a Mundipharma collaboration and an anticipated sNDA filing. The market has already moved, with CRMD up ~16.8% on the news, but that’s below a typical 20%+ headway that usually prices a biotech story fully. Technicals are mixed: short-term SMA is supportive, but MACD sits below its signal and 50-day SMA is resistance. Bottom line: we lean bullish. The quarter shows real commercial traction and clearer path to label expansion, so upside feels real but not runaway, so size risk accordingly.